[Refractory anemia with partial blastosis. A new therapeutic approach].
Refractory anaemia with partial myeloblastosis is classified among myelodysplasia syndromes which are characterized by abnormalities in the differentiation of haematopoietic cells, but it differs from these syndromes in that blast cells are in excess and the prognosis is darker. So far, this type of anaemia has resisted all treatment. The possibility of differentiating leukaemic cells in vitro has opened new therapeutic prospects.
Chomienne
C
C
Service de Médecine nucléaire, Hôpital Saint-Louis, Paris.
Thomas
G
G
Najean
Y
Y
Degos
L
L
D015250:Aclarubicin / Q000627:therapeutic use; D000754:Anemia, Refractory, with Excess of Blasts / Q000188:drug therapy*; D002762:Cholecalciferol / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003115:Colony-Stimulating Factors / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006133:Growth Substances / Q000627:therapeutic use; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D015474:Isotretinoin / Q000627:therapeutic use; D011379:Prognosis; D012074:Remission Induction
D003115:Colony-Stimulating Factors; D006133:Growth Substances; D003561:Cytarabine; D002762:Cholecalciferol; D015250:Aclarubicin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D007372:Interferons; D015474:Isotretinoin
Anémies réfractaires à blastose partielle. Nouvelle approche thérapeutique.